Preventive Efficacy and Safety of Yiqi-Wenjing-Fang Granules on Oxaliplatin-Induced Peripheral Neuropathy: A Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Zhancheng Gu,1 Guoli Wei,2 Liangjun Zhu,3 Lingjun Zhu,4 Jing Hu,5 Qi Li,6 Guoxiang Cai,7 Hong Lu,8 Min Liu,9 Chen Chen,10 Yi Ji,2 Guochun Li,11 and Jiege Huo1,2

1The Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210046, China
2Department of Oncology, Jiangsu Provincial Hospital of Integrated Chinese and Western Medicine, Nanjing 210046, China
3Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing 210009, China
4Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
5Department of Medical Oncology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
6Department of Oncology, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China
7Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China
8Department of Chemotherapy, Changshu No. 1 People’s Hospital, Chuzhou 239001, China
9Department of Oncology, Suzhou Hospital of Traditional Chinese Medicine, Suzhou 215002, China
10Department of Oncology, Yancheng Hospital of Traditional Chinese Medicine, Yancheng 224005, China
11School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210046, China

Correspondence should be addressed to Jiege Huo; huojiege@jsatcm.com

Received 27 January 2021; Revised 1 September 2021; Accepted 20 September 2021; Published 29 September 2021

Background. Oxaliplatin-induced peripheral neuropathy (OIPN) is one of the most common side effects of oxaliplatin, which can cause reduction and cessation of oxaliplatin-based chemotherapy and significantly affect patients’ quality of life. However, no drug has yet been recognized to prevent or treat OIPN. Yiqi-Wenjing-Fang (YWF) is a joint name of Chinese medicine prescriptions with similar effects of tonifying qi and warming meridians, represented by Huangqi Guizhi Wuwu decoction (HGWD) and Danggui Sini decoction (DSD), both from “Treatise on Cold Pathogenic and Miscellaneous Diseases.” YWF granules, including HGWD granules and DSD granules, have been respectively demonstrated to be effective in preventing OIPN in previous small-sample observations. The purpose of this study is to enlarge the sample size for further evaluation of the preventive efficacy and safety of YWF granules on OIPN.

Methods and Analysis. This study is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. 360 postoperative patients with stage IIa–IIIc colorectal cancer will be randomly assigned into placebo-control group, intervention group I, and intervention group II, taking the mimetic granules of YWF as placebo, HGWD granules and DSD granules, respectively. All subjects will receive oxaliplatin-based chemotherapy regimen at the same time. EORTC QLQ-CIPN20 will be used to assess the degree of OIPN as the primary outcome measure. The grades of OIPN, quality of life, chemotherapeutic efficacy, and the number of completed chemotherapy cycles are selected as the secondary outcome measures. Discussion. Based on the condition of no recognized effective drugs in preventing OIPN, evidence-based medical study will be conducted for seeking a breakthrough in the field of Chinese herb medicine. This protocol could provide reliable and systemic research basis about the efficacy of YWF granules and the differentiation of two classical prescriptions of YWF on preventing OIPN objectively. Trial Registration. This study was registered at ClinicalTrials.gov on 26 December 2020 (ID: https://clinicaltrials.gov/ct2/show/NCT04690283).
1. Introduction

Oxaliplatin is a prime drug in the first-line standard chemotherapy regimens of colorectal cancer, included in mFOLFOX6, FOLFOX4, XELOX, and so on. The main side effect is dose-dependent neurotoxicity, namely, oxaliplatin-induced peripheral neuropathy (OIPN), which is the primary cause of reduction and cessation of platinum-based chemotherapy. Acute OIPN usually will develop in hours of oxaliplatin infusion and peaks 3 days later. About 90% of patients will undergo acute OIPN symptoms, characterized by abnormal sensations and muscle spasm of perioral region, tongue, throat, jaw, and limbs, triggered by cold stimulation. These acute symptoms can alleviate in a week or so but will recur as the next chemotherapy cycle comes subsequently [1, 2]. Chronic OIPN will gradually develop and aggravate after approximately 3 months of repeated administration, usually with more than 540 mg/m² cumulative dose of oxaliplatin. Clinical manifestations of chronic OIPN are bilateral symmetric paresthesia, dysesthesia and/or allodynia of limbs (“glove-sock” distribution), disorder of fine motor coordination, sensory ataxia, and autonomic nervous dysfunction, persisting as long as 6 months or even years after the termination of treatment [2–4].

Through exploring the mechanism of OIPN, researchers have been trying to find potential prophylactic or therapeutic drugs all the time. Numerous clinical and preclinical studies have reported a series of effective agents for OIPN, such as calcium and magnesium injections [5], carbamazepine [6], oxcarbazepine [7], venlafaxine [8], gabapentin [9], pregabalin [10], glutathione [11], glutamine [12], alphalipoic acid [13], amifostine [14], Vitamin E [15], monosialoganglioside (GM1) [16], and novel agents such as niclosamide [17], fingolimod [18], N-acetylcysteine [19], minicrappan [20], riluzole [21], and a selective sigma-1 receptor antagonist MR309 [22]. Nonetheless, most studies either get negative results on further validation or remain at early stages, so that seldom drug has received recognition yet [1, 23]. According to the updated American Society of Clinical Oncology (ASCO) guideline, duloxetine is the only recommended treatment agent for patients with established painful OIPN. However, limited benefits and unfavorable side effects decrease the support of duloxetine [24, 25]. Besides, some of the nondrug treatment strategies, like exercise, scrambler therapy, cryotherapy, and compression therapy, are moderately recommended for further study for their potential benefits and reasonably safety but still lack strong evidence [26–28]. Therefore, seeking effective agents for OIPN is still an urgent and significant task.

According to the clinical characteristics, OIPN corresponds with “Bizheng” from the theory of traditional Chinese medicine (TCM), interpreted as arthromyodynia. Considering the hypoimmunity of patients receiving chemotherapy, deficiency of qi and meridian impassability are regarded as the vital pathogenesis of OIPN [29]. Yiqi-Wenjing-Fang (YWF) is a joint name of TCM prescriptions with similar effects of tonifying qi and warming meridians, represented by Huangqi Guizhi Wuwu decoction (HGWD) and Danggui Sini decoction (DSD), both from “Treatise on Cold Pathogenic and Miscellaneous Diseases.” Comparing the two representative prescriptions, HGWD is better at tonifying qi, while DSD is better at warming meridians. Our previous small-sample-size randomized controlled clinical trial (n = 72) showed that HGWD could effectively prevent OIPN through reducing the incidence and alleviating the symptoms of OIPN without affecting the chemotherapy efficacy [30]. Further mechanistic studies preliminarily revealed the correlation between HGWD and platinum transport and accumulation in dorsal root ganglion (DRG), as well as inflammatory responses, oxidative stress, axonal lesions, and neuronal and mitochondrial dysfunctions induced by platinum chelate [31, 32]. We conducted another randomized controlled clinical trial (n = 48) about DSD, which showed that DSD could significantly decrease the incidence and severity of acute OIPN [33]. Mechanistic studies demonstrated that the protective effects of DSD could be related to suppressing inflammatory lesions, improving ultrastructural morphologies, and enhancing amounts of Nissl bodies in DRG [34]. Although YWF has a strong clinical research basis in the efficacy and safety of OIPN prevention, further studies are necessary due to the insufficient sample size and the lack of placebo and parallel controls previously.

2. Method and Analysis

2.1. Objective. YWF have been empirically used to treat arthromyodynia for a long time in China, represented by HGWD and DSD, but there is a lack of evidence-based medical study. Small-sample-size clinical studies and animal experiments have been conducted and indicated positive efficacy of YWF granules on OIPN. To enlarge the sample size for further evaluation, 360 subjects for eligibility will be recruited. In addition, in order to compare the preventive efficacy on OIPN between HGWD granules and DSD granules, two paratactic treatment groups will be set according to the theory of treatment based on syndrome differentiation.

2.2. Study Design. This study is designed as a randomized, double-blind, placebo-controlled, and multicenter clinical trial that will last for 18 months from January 2021 to June 2022. It will be conducted in 30 clinical centers in China, and each center will have an investigator for enrolling the patients and collecting the data. The centers and their investigators are listed in Table 1.

The trial was registered at ClinicalTrials.gov (ID: NCT04690283), and the protocol version is 1.2/20200506. The flow chart is shown in Figure 1. The schedule of enrollment, interventions, and assessments is shown in Figure 2.
2.3. Eligibility Criteria

2.3.1. Inclusion Criteria

(i) Subject diagnosed with stage IIa-IIIc colorectal cancer, confirmed by histopathological examination, according to Chinese Society of Clinical Oncology (CSCO) guidelines for diagnosis and treatment of colorectal cancer.

(ii) Subject suitable for receiving FOLFOX4 or mFOLFOX6 or XELOX as adjuvant chemotherapy after radical resection of colorectal cancer, receiving each dose and cumulative dose of oxaliplatin of $85 \text{mg/m}^2$ and $\geq 540 \text{mg/m}^2$, respectively.

(iii) Subject with Karnofsky Performance Status Scale (Schag et al. 1984) index $\geq 60$ points and an expected survival time $\geq 6$ months.

(iv) Subject aged between 18 and 80 years, men or women.

(v) Subject without severe damage of the heart, liver, kidney, or hematopoietic system.

2.3.2. Exclusion Criteria

(i) Subject with any grade of peripheral neuropathy.

(ii) Subject who has ever received treatment of neurotoxic chemotherapeutics, such as oxaliplatin, cisplatin, taxanes, or vinca alkaloids.

(iii) Subject who is receiving agents with potential preventive or therapeutic effects to neuropathy, such as duloxetine, carbamazepine, venlafaxine, gabapentin, pregabalin, phenytoin, valproate, milnacipran, or tricyclic antidepressant.

(iv) Subject who is participating or have participated in other clinical trials.

(v) Subject with a family history of hereditary/familial neuropathy.

Table 1: Clinical centers in China.

| No. | Organization name                                      | Location                 | Investigator       |
|-----|-------------------------------------------------------|--------------------------|--------------------|
| 1   | Jiangsu Province Hospital on Integration of Chinese and Western Medicine | Nanjing, Jiangsu Province | Jiege Huo          |
| 2   | Sir Run Run Hospital                                  | Nanjing, Jiangsu Province | Fubing Wu          |
| 3   | Yancheng Hospital of Traditional Chinese Medicine     | Yancheng, Jiangsu Province | Jianlin Xu         |
| 4   | Jiangning District Hospital of Traditional Chinese Medicine | Nanjing, Jiangsu Province | Zhen Wang          |
| 5   | Suzhou Hospital of Traditional Chinese Medicine       | Suzhou, Jiangsu Province | Min Liu            |
| 6   | Huai’an Hospital of Traditional Chinese Medicine       | Huai’an, Jiangsu Province | Aifei Chen         |
| 7   | Zhenjiang Hospital of Chinese Traditional and Western Medicine | Zhenjiang, Jiangsu Province | Dong Fang          |
| 8   | Changshu No. 1 People’s Hospital                     | Changshu, Jiangsu Province | Hong Lu            |
| 9   | Affiliated Nanjing Jiangbei People’s Hospital of Nantong University | Nanjing, Jiangsu Province | Ge Feng            |
| 10  | The First People’s Hospital of Chuzhou                | Chuzhou, Anhui Province  | Aimin Chen         |
| 11  | Shanghai Changzheng Hospital                          | Shanghai                 | Xiaojianqiang Yue  |
| 12  | Nantong Tumor Hospital                                | Nantong, Jiangsu Province | Chunming Xu        |
| 13  | Danyang Hospital of Traditional Chinese Medicine      | Danyang, Jiangsu Province | Guofang Wang       |
| 14  | Nanjing Drum Tower Hospital                           | Nanjing, Jiangsu Province | Xiaoqing Qian      |
| 15  | Jiangsu Cancer Hospital, the Affiliated Cancer Hospital of Nanjing Medical University | Nanjing, Jiangsu Province | Liangjun Zhu       |
| 16  | Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University | Nanjing, Jiangsu Province | Liangjun Zhu       |
| 17  | Fudan University Shanghai Cancer Center               | Shanghai                 | Guoxiang Cai       |
| 18  | Longhua Hospital Shanghai University of Traditional Chinese Medicine | Shanghai                 | Zhongqi Wang       |
| 19  | Changhai Hospital                                     | Shanghai                 | Xiaoqianqiang Zhai |
| 20  | Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine | Shanghai                 | Qi Li              |
| 21  | Yangzhou Hospital of Traditional Chinese Medicine     | Yangzhou, Jiangsu Province | Xiaochun Zhang     |
| 22  | Zhejiang Provincial Hospital of Chinese Medicine      | Hangzhou, Zhejiang Province | Qijin Shu          |
| 23  | Hangzhou Hospital of Traditional Chinese Medicine     | Hangzhou, Zhejiang Province | Shengyou Lin       |
| 24  | The First Affiliated Hospital of Guangxi University of Chinese Medicine | Nanning, Guangxi Province | Zhen Rong          |
| 25  | Henan Cancer Hospital                                 | Zhengzhou, Henan Province | Huaimin Liu        |
| 26  | Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University | Luzhou, Sichuan Province | Zhongming Yang     |
| 27  | Affiliated Hospital of Shanxi University of Traditional Chinese Medicine | Xianyang, Shanxi Province | Renting Li         |
| 28  | Hunan Academy of Traditional Chinese Medicine Affiliated Hospital | Changsha, Hunan Province | Puhua Zeng         |
| 29  | Hebei General Hospital                                | Shijiazhuang, Hebei Province | Qingxia Li        |
| 30  | The First Affiliated Hospital of Guizhou University of Chinese Medicine | Guiyang, Guizhou Province | Xindong Tang       |

Note. Each center was randomly assigned the center number, and the ranking had nothing to do with the center scale and the number of planned enrollment.
(vi) Subject who cannot take drugs orally.
(vii) Subject with mental illness who cannot cooperate.
(viii) Pregnant or lactation period women.

2.3.3. Termination Criteria

(i) Subject withdraws from informed consent.
(ii) Disease progression of subject is confirmed by imageological examination or clinical assessment.
(iii) Subject experienced adverse events that the investigator deemed necessary to terminate trial treatment.
(iv) Subject experienced severe side effects that the investigator deemed necessary to terminate trial treatment.
(v) Subject who stops or discontinues their medication without authorization.
(vi) Subject who is less compliant with trial regulations intentionally or unintentionally.
(vii) Other circumstances that may be detrimental to subject.

2.4. Sample Size Calculation. This study is suitable for superiority test. Although without positive-control group, the method of sample size calculation is equal to the three-arm trial. Based on the incidence of OIPN, the incidence of the placebo-control group was assumed as 40%, and the incidences of two intervention groups were both assumed as 20%. The Pearson chi-square test was used to calculate the appropriate sample size for each group. Taking the 20% shedding rate into account and rounding off, each group needs 120 samples and a total of 360 samples.

2.5. Randomization, Allocation, and Blinding. Randomization and blinding are controlled from the drug production source. All the test drugs are designed with the same appearance, dose, and smell, and each drug package has a corresponding drug number. Every six drug numbers are formed into a group, randomly corresponding to six test drugs, which necessarily include two mimetic granules of YWF, two HGWD granules, and two DSD granules, so that the whole is in accordance with the ratio of 1:1:1. Each center must recruit subjects in units of six (at least six subjects), and each recruited subject will be randomly assigned a sequential number and a corresponding drug number. Although the sequential and drug numbers are public, the specific properties of the drug are unknown to anyone, including subjects, investigators, and third-party inspectors.

2.6. Intervention. All subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen, listed in Table 2, and YWF granules or placebo at the same time. In order to control the dosage of Chinese herbal medicine, the standard granules will be used as the intervention dosage form in this study, provided by Tianjin Hongri Kangrentang.
| STUDY PERIOD | Enrollment (cycle±day) | Allocation (cycle±day) | Post allocation (cycle) | Post allocation (month after the last cycle) |
|--------------|------------------------|------------------------|-------------------------|---------------------------------------------|
| TIME POINTS  | 1-2                    | 1-1                    | 1                       | 2                                           |
|              |                        |                        | 3                       | 4                                           |
|              |                        |                        | 5                       | 6                                           |
|              |                        |                        | 1                       | 3                                           |
|              |                        |                        | 6                       | 12                                          |

**ENROLLMENT**
- Eligibility screening (inclusion/exclusion) ×
- Informed consent x
- Randomized ×

**INTERVENTION**
- Oxaliplatin-based chemotherapy regimen × × × × × × ×
- Administration of investigational product × × × × × × ×

**ASSESSMENT**
- Degree of OIPN (EORTC QLQ-CIPN20) × × × × × × × × × × ×
- Grades of OIPN (NCI-CTCAE 5.0) × × × × × × × × × × ×
- Quality of life (EORTC QLQ-C30) × × × × × × × × × × ×
- Chemotherapeutic efficacy (RESIST 1.1) × × × × × × ×
- Number of completed chemotherapy cycles ×

**Figure 2:** Schedule of enrollment, allocation, intervention, and assessment. Note: Subjects will complete the EORTC QLQ-CIPN20 questionnaire for 4 consecutive times during cycle 1 (refer to 2.8). EORTC QLQ-CIPN20: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale; NCI-CTCAE 5.0: National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer’s Core Quality of Life Questionnaire; RECIST 1.1: Response Evaluation Criteria in Solid Tumors Version 1.1.

**Table 2:** Chemotherapy regimen.

| Abbreviated name | Components            | Dosage       | Mode of administration | Treatment course       |
|------------------|-----------------------|--------------|------------------------|------------------------|
| FOLFOX4          | Oxaliplatin          | 85 mg/m²     | Intravenous infusion   | Every 2 weeks, at least 3 cycles |
|                  | Leucovorin 5-Fluorouracil | 200 mg/m²  | ≥ 2 hours on day 1     |                        |
|                  |                       | 400 mg/m²    | Intravenous infusion   |                        |
|                  |                       | 600 mg/m²    | ≥ 2 hours on days 1 and 2 |                      |
|                  |                       |              | Intravenous injection  |                        |
|                  |                       |              | on days 1 and 2        |                        |
|                  |                       |              | Continuous intravenous  |                        |
|                  |                       |              | infusion for 22 hours  |                        |
|                  |                       |              | on days 1 and 2         |                        |
| mFOLFOX6         | Oxaliplatin          | 85 mg/m²     | Intravenous infusion   | Every 2 weeks, at least 3 cycles |
|                  | Leucovorin 5-Fluorouracil | 400 mg/m²  | ≥ 2 hours on day 1     |                        |
|                  |                       | 400 mg/m²    | Intravenous infusion   |                        |
|                  |                       | 1200 mg/m²   | ≥ 2 hours on day 1      |                        |
|                  |                       |              | Intravenous injection  |                        |
|                  |                       |              | on day 1               |                        |
|                  |                       |              | Continuous intravenous  |                        |
|                  |                       |              | infusion for 22 hours  |                        |
|                  |                       |              | on days 1 and 2         |                        |
| XELOX            | Oxaliplatin          | 130 mg/m²    | Intravenous infusion   | Every 3 weeks, at least 4 cycles |
|                  | Capecitabine         | 1000 mg/m²   | ≥ 2 hours on day 1      |                        |
|                  |                       |              | Oral administration    |                        |
|                  |                       |              | twice a day on days 1–14|                        |
Pharmaceutical Co. LTD., China, listed in Table 3. Besides, any other drugs potentially affecting the results of the experiment will be forbidden in the whole trial process, such as ganglioside, calcium and magnesium mixture agent, glutathione, mecobalamin, and injections containing astragalus.

2.6.1. Placebo-Control Group. From the beginning of chemotherapy, subjects in this group will take the mimetic granules of YWF brewed by warm water after meal twice a day (once 1 bag, 1 hour after breakfast and dinner) for at least 3 months. The mimetic granules of YWF, which contain 2.5% HGWD granules, 2.5% DSD granules, bitter principle, food colouring, and starch, are designed with the same appearance and dosage and similar smell and taste to YWF granules.

2.6.2. Intervention Group I. From the beginning of chemotherapy, subjects in this group will take HGWD granules brewed by warm water after meal twice a day (once 1 bag, 1 hour after breakfast and dinner) for at least 3 months.

2.6.3. Intervention Group II. From the beginning of chemotherapy, subjects in this group will take DSD granules brewed by warm water after meal twice a day (once 1 bag, 1 hour after breakfast and dinner) for at least 3 months.

2.7. Outcomes. In order to observe the dynamic change of OIPN severity and quality of life (QOL) to give evidence-based evaluations, this trial sets multiple measure time points.

2.7.1. Primary Outcome

(i) The degree of oxaliplatin-induced peripheral neuropathy will be evaluated according to the score of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale (EORTC QLQ-CIPN20, 20–80 scores, with higher scores meaning a worse outcome), which is evaluated by the subject on 1 day before and 3 consecutive days after the first time of oxaliplatin administration. Subsequent assessments will be made every one time from cycle 2 to cycle 6, 1 month after the end of cycle 6, and then every 3 months up to 1 year.

2.7.2. Secondary Outcome

(i) The grades of oxaliplatin-induced peripheral neuropathy will be evaluated according to the grades of National Cancer Institute-Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE 5.0, 0–5 grades, with higher grade meaning a worse outcome), which is evaluated by the doctor on 1 day before the oxaliplatin administration from cycle 1 to cycle 6, 1 month after the end of cycle 6, and then every 3 months up to 1 year.

2.8. Safety Assessment. All adverse events and reactions will be recorded in detail, including the variety, occurrence time, incidence, severity, duration, therapeutic measures, and outcomes. Some examinations should be taken to monitor the adverse events and reactions, including blood routine examination, stool routine examination, liver function test, renal function test, electrocardiograph (ECG), computed tomography (CT), and magnetic resonance imaging (MRI). It should be highlighted and analyzed in particular about the abnormal inspection indicators, cases of study suspension due to adverse events, and the causality between the adverse events and the test drugs.

2.9. Data Management and Monitoring. For efficient and convenient statistics, this study will adopt electronic case report form (eCRF) to record data. The data inputter in each center should timely and accurately record data and upload it to the statistical system after requesting and obtaining the sequential number and the random grouping code. After being reviewed by the inspectors and checked by the data administrator, the data will be locked for statistical analysis subsequently.

This clinical trial will introduce a third-party monitoring team to strengthen the research quality control during the whole process. In accordance with the Good Clinical Practice (GCP) requirements issued by the State Food and Drug Administration (SFDA), a dedicated inspector will be assigned to make regular on-site monitoring visits to the clinical centers to ensure strict adherence to the protocol and correct filling of the test data.

2.10. Statistical Analysis. This study cooperates with Statistics Department of Nanjing University of Traditional Chinese Medicine. After the test trial is determined, a special statistician will be employed for making the statistical analysis plan. All data will be statistically analyzed by SAS 9.3 software. Enumeration data will be expressed as percentage, while measurement data will be expressed as mean ± standard deviation. For comparison of count or grade data, chi-square test will be used. Two logistic
multiple regressions (Enter method) will be used to analyze the factors affecting the objective curative effect.

3. Discussion

Oxaliplatin is a standard chemotherapy drug for colorectal cancer, and its toxic and side effects must be taken seriously. OIPN is the most common side effect which significantly affects the curative efficacy of chemotherapy and patients’ quality of life and remains a refractory problem despite receiving extensive attention from researchers.

For seeking potential effective therapy, the pathogenesis of OIPN has been studied for a long time. Analysis of recent literature suggested that the alteration of voltage-gated Na⁺ channels, K⁺ channels, Ca²⁺ channels, and transient receptor potential (TRP) channels could be related to acute OIPN [2]. On the other hand, platinum accumulating in dorsal root ganglion so as to cause a series of neuronal damage, including nuclear DNA damage, mitochondrial dysfunction, oxidative stress, and axonopathy, is considered as the main mechanism of chronic OIPN [2, 35]. Regarding platinum accumulation, organic cation transporter 2 (OCT2) has been demonstrated to play an important role in platinum uptake and is expected to be a new target for prevention and treatment of OIPN [36, 37].

A number of agents have been proposed with potential therapeutic or preventive effects to OIPN. However, none of them have got recognition by further studies [1, 23]. Combining the theory of TCM, this study attributes OIPN to “arthromyodynia” [29]. YWF granules are a category of prescription granules with similar effects of tonifying qi and warming meridians, and they have been empirically used to treat arthromyodynia in China. In order to obtain scientific and precise evidence, several animal studies and randomized controlled clinical trials with small sample size have been conducted previously. Results showed that YWF granules can ameliorate OIPN syndrome without affecting the antitumor activity of oxaliplatin [30, 33]. Thus, we have designed the protocol for a randomized, placebo-controlled, double-blind, multicenter trial to enlarge the sample size for further evaluation of the preventive efficacy and safety of YWF granules. This study will provide objective evidence for the clinical application of YWF granules in preventing OIPN.

Data Availability

The data and materials are available upon request from the corresponding author.

Ethical Approval

Ethical approval was obtained from the Ethics Committee of Jiangsu Provincial Hospital of Traditional Chinese and Western Medicine in Nanjing, China (approval no. 2020LAKY014). The study protocol is in accordance with the guidelines of the Declaration of Helsinki, formulated by the World Medical Association.

Consent

Patients meeting the inclusion criteria and/or their legal representatives will be required to attend the discussion about this study and will be given sufficient time to consider whether to participate. Written informed consent will be obtained from patients or their legal representatives, and personal information will be kept with utmost secrecy.

Disclosure

The funders have no role in research design, data collection, management, analysis or interpretation, report writing, or submission decisions, and they have no final authority over any of these activities.

Conflicts of Interest

The authors declare that they have no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

ZCG and GLW contributed equally to this work. JGH conceived and designed the study and is responsible for the coordination of the study. ZCG and GLW developed the

| Table 3: Standard formulation of YWF granules. |
|-----------------------------------------------|
| Pinyin name | English name | Latin name | Doses, g |
|----------------|----------------|----------------|-------------|
| Huangqi | *Astragalus membranaceus* | *Astragali Radix Membranacei* | 18 |
| Guizhi | Cassia twig | Ramulus Cinnamomi | 9 |
| Baishao | Radix Paeoniae Alba | *Paeoniae Radix Alba* | 9 |
| Shengjiang | Ginger | *Rhizoma Zingiberis Recens* | 9 |
| Dazao | Jujube | *Fructus Zizyphi Jujubae* | 9 |

| Pinyin name | English name | Latin name | Doses, g |
|----------------|----------------|----------------|-------------|
| Danggui | *Angelica sinensis* | *Angelicae sinensis* | 12 |
| Guizhi | Cassia twig | Ramulus Cinnamomi | 9 |
| Baishao | Radix Paeoniae alba | *Paeoniae Radix Alba* | 9 |
| Xixin | Asarum | Herba Asari Cum Radice | 3 |
| Tongcao | Tetrapanax papyrifer | Medulla Tetrapanacis Papyriferi | 6 |
| Zhigancao | Honey-fried licorice root | *Radix Glycyrrhizae Preparata* | 5 |
| Dazao | Jujube | *Fructus Zizyphi Jujubae* | 9 |
study design and revised the protocol. LJZ, LJZ, JH, QL, GXC, HL, ML, and CC participated in the work of enrolling the patients and collecting the data. JGH and YJ sought funding and ethical approval. All the authors contributed to the writing of the manuscript and read and approved the final manuscript.

Acknowledgments

The authors would like to thank the patient advisers for the help in designing this protocol. This work was supported by the National Natural Science Foundation of China (no. 82004339), Project of National Clinical Research Base of Traditional Chinese Medicine in Jiangsu Province, China (no. JD2019SZXYB02), Scientific Research Project of Jiangsu Provincial Health Commission (no. H2019095), and Jiangsu Science and Technology Department Social Development- Clinical Frontier Technology (nos. BE2019787 and BRA2019100).

References

[1] S. Kinga, “Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity,” Pharmacological Reports, vol. 72, pp. 508–527, 2020.

[2] K. Lumei, T. Yuyang, X. Shilin, and C. Hongping, “Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment,” Journal of Neurology, vol. 268, 2020.

[3] W. Xiaoman, C. Xiaofeng, S. Peng et al., “Study on efficacy and safety of Huangqi Guizhi decoction treatment for oxaliplatin induced peripheral neurotoxicity,” Medicine, vol. 99, no. 22, Article ID e19923, 2020.

[4] D. R. Pachman, R. Qin, D. K. Seisler et al., “Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance),” Journal of Clinical Oncology, vol. 33, no. 30, pp. 3416–3422, 2015.

[5] C. L. Loprinzi, R. Qin, S. R. Dakhil et al., “Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/alliance),” Journal of Clinical Oncology, vol. 32, no. 10, pp. 997–1005, 2014.

[6] S. von Delius, F. Ekel, S. Wagenpfel et al., “Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study,” Investigational New Drugs, vol. 25, no. 2, pp. 173–180, 2007.

[7] A. A. Argyriou, E. Chroni, P. Polychronopoulos et al., “Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy,” Neurology, vol. 67, no. 12, pp. 2253–2255, 2006.

[8] J. P. Durand, G. Deplanque, V. Mountheil et al., “Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial,” Annals of Oncology, vol. 23, no. 1, pp. 200–205, 2012.

[9] M. Ohsawa, S. Otake, T. Murakami, S. Yamamoto, T. Makino, and H. Ono, “Gabapentin prevents oxaliplatin-induced mechanical hyperalgesia in mice,” Journal of Pharmacological Sciences, vol. 125, no. 3, pp. 292–299, 2014.

[10] D. C. de Andrade, M. Jacobsen Teixeira, R. Galhardoni et al., “Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized, double-blind trial,” The Oncologist, vol. 22, no. 10, pp. 1154–e105, 2017.

[11] S. Cascini, V. Catalano, L. Cordella et al., “Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial,” Journal of Clinical Oncology, vol. 20, no. 16, pp. 3478–3483, 2002.

[12] W. S. Wang, J. K. Lin, T. C. Lin et al., “Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients,” The Oncologist, vol. 12, no. 3, pp. 312–319, 2007.

[13] Y. Guo, D. Jones, J. L. Palmer et al., “Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial,” Supportive Care in Cancer, vol. 22, no. 5, pp. 1223–1231, 2014.

[14] A. F. Pereira, J. A. Lino, B. W. F. Alves et al., “Amifostine protects from the peripheral sensory neuropathy induced by oxaliplatin in mice,” Brazilian Journal of Medical and Biological Research, vol. 53, no. 11, Article ID e10263, 2020.

[15] Z. Salehi and M. Roayaei, “Effect of Vitamin E on oxaliplatin-induced peripheral neuropathy prevention: a randomized controlled trial,” International Journal of Preventive Medicine, vol. 6, p. 104, 2015.

[16] D. s. Wang, Z. q. Wang, G. Chen et al., “Phase III randomized, placebo-controlled, double-blind study of monooctetetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer,” Cancer Medicine, vol. 9, no. 1, pp. 151–159, 2020.

[17] O. Cerles, E. Benoit, C. Ch´ereau et al., “Niclosamide inhibits oxaliplatin neurotoxicity while improving colorectal cancer therapeutic response,” Molecular Cancer Therapeutics, vol. 16, no. 2, pp. 300–311, 2017.

[18] S. G. Dorsey, I. R. Kleckner, D. Barton et al., “The national cancer Institute clinical trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neurotoxic,” Journal of the National Cancer Institute, vol. 111, no. 6, pp. 531–537, 2019.

[19] N. Bondad, R. Boostani, A. Barri, S. Elyasi, and A. Allahyari, “Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: a randomized, double blind, placebo-controlled, clinical trial,” Journal of Oncology Pharmacy Practice, vol. 26, no. 7, pp. 1575–1582, 2020.

[20] T. Andoh, R. Kitamura, and Y. Kuraishi, “Milnacipran inhibits oxaliplatin-induced mechanical allodynia through spinal action in mice,” Biological and Pharmaceutical Bulletin, vol. 38, no. 1, pp. 151–154, 2015.

[21] T. Trinh, S. B. Park, J. Murray et al., “Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial,” Supportive Care in Cancer, vol. 29, no. 2, pp. 1103–1110, 2021.

[22] J. Brun and R. Velasco, “Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy,” Neural Regeneration Research, vol. 13, no. 5, pp. 775–778, 2018.

[23] A. Avan, T. J. Postma, C. Cirrincione et al., “Platinum-induced neurotoxicity and preventive strategies: past, present, and future,” The Oncologist, vol. 20, no. 4, pp. 411–432, 2015.

[24] E. M. L. Smith, H. Pang, C. Cirrincione et al., “Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy,” Journal of the American Medical Association, vol. 309, no. 13, pp. 1359–1367, 2013.
[25] L. L. Charles, L. Christina, B. Jonathan et al., “Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update,” *Journal of Clinical Oncology*, vol. 38, no. 28, pp. 3325–3348, 2020.

[26] A. J. M. Beijers, C. S. Bonhof, F. Mols et al., “Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy,” *Annals of Oncology*, vol. 31, no. 1, pp. 131–136, 2020.

[27] S. Eldridge, L. Guo, and J. Hamre, “A comparative review of chemotherapy-induced peripheral neuropathy in vivo and in vitro models,” *Toxicologic Pathology*, vol. 48, no. 1, pp. 190–201, 2020.

[28] L. Poupon, N. Kerckhove, J. Vein et al., “Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives,” *Expert Opinion on Drug Safety*, vol. 14, no. 8, pp. 1269–1282, 2015.

[29] C. Peng, Y. Jie, H. Jiege, C. Xueling, and W. Xiaoning, “Treatment of chemotherapy-related peripheral neuropathy with traditional Chinese medicine from the perspective of blood-arthralgia Zheng,” *T’ang Studies*, vol. 2, no. 4, p. e30, 2012.

[30] X. Cheng, J. Huo, D. Wang et al., “Herbal medicine AC591 prevents oxaliplatin-induced peripheral neuropathy in animal model and cancer patients,” *Frontiers in Pharmacology*, vol. 8, p. 344, 2017.

[31] G. Wei, Z. Gu, J. Gu et al., “Platinum accumulation in oxaliplatin-induced peripheral neuropathy,” *Journal of the Peripheral Nervous System*, vol. 26, no. 1, pp. 35–42, 2021.

[32] G. L. Wei, Z. C. Gu, L. C. Li et al., “Experimental study of Huangqi guizhi wuwu decoction to prevent oxaliplatin-induced chronic peripheral neuropathy by reducing platinum accumulation,” *Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology*, vol. 7, no. 21, pp. 1467–1473, 2019.

[33] R. Ding, J. G. Huo, and Y. Wang, “Clinical observation on Danggui sini decoction in preventing and treating oxaliplatin neurotoxicity,” *Journal of Nanjing University of Traditional Chinese Medicine*, vol. 5, no. 30, pp. 432–433, 2014.

[34] R. Ding, Y. Wang, J.-P. Zhu et al., “Danggui Sini decoction protects against oxaliplatin-induced peripheral neuropathy in rats,” *Journal of Integrative Neuroscience*, vol. 19, no. 4, pp. 663–671, 2020.

[35] L. E. Ta, L. Espeset, J. Podratz, and A. J. Windebank, “Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding,” *Neurotoxicology*, vol. 27, no. 6, pp. 992–1002, 2006.

[36] J. A. Sprowl, G. Ciarimboli, C. S. Lancaster et al., “Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2,” *Proceedings of the National Academy of Sciences*, vol. 110, no. 27, pp. 11199–11204, 2013.

[37] I. Buß, A. Hamacher, N. Sarin, M. U. Kassack, and G. V. Kalayda, “Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells,” *Metallomics*, vol. 10, no. 3, pp. 414–425, 2018.